Vernalis (R&D) Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vernalis (R&D) Ltd.
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.
A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.
Hanmi aims to commercialize its GLP-1 obesity treatment, the first one from its ambitious HOP project, within three years as it moves to Phase III in Korea.
- Other Names / Subsidiaries
- Cita NeuroPharmaceuticals
- Vernalis Group plc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.